Physician profile
Paul Jew
NPI 1114086253
$3,071.00
in general payments reported to CMS, 2019-2025
15 companies · $44.70 in 2025
The $44.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $567 · 2021: $407 · 2022: $512 · 2023: $212 · 2024: $320 · 2025: $44.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $897.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.59 | 2019-2025 | Jardiance |
| Pfizer INC. | $480.77 | 2019-2021 | |
| Lilly USA, LLC | $286.90 | 2019-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $184.94 | 2022 | |
| Merck Sharp & Dohme LLC | $137.33 | 2019-2021 | |
| Celgene Corporation | $118.45 | 2019 | |
| Novo Nordisk INC | $96.94 | 2020-2021 | |
| Amgen INC. | $91.92 | 2021-2023 | |
| Abbott Laboratories | $70.27 | 2022-2023 | Proclaim |
| Boston Scientific Corporation | $20.96 | 2023 | Watchman Access System |
| Teva Pharmaceuticals USA, INC. | $19.30 | 2020 | |
| Glaxosmithkline, LLC. | $13.20 | 2023 | Trelegy Ellipta |
| Genentech USA, INC. | $11.49 | 2020 | |
| Amarin Pharma, INC. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.